FAQs

Yes. The complement field has entered a pivotal period of growth and maturation. Recent milestones, including Regeneron's cemdisiran progressing through FDA and EMA review and Biogen's acquisition of Apellis, demonstrate growing industry investment and confidence in complement therapeutics. At the same time, developers are increasingly focused on differentiating their assets through novel targets, modalities, biomarkers and indication strategies.

As pipelines expand beyond traditional C3 and C5 approaches, attending the summit provides an opportunity to stay ahead of emerging scientific developments, benchmark your strategy against industry leaders and understand how complement biology is being translated into new therapeutic opportunities across CNS, ocular, oncology, autoimmune and renal diseases.

The summit brings together a highly focused audience of 80+ experts dedicated to complement therapeutics, creating a collaborative environment for scientific discussion, networking and partnership building.

Attendees typically work across:

• Discovery Biology
• Immunology
• Translational Medicine
• Biomarker Development
• Clinical Development
• Precision Medicine
• Drug Discovery
• R&D

The audience includes representatives from biotech, pharma, academic institutions and emerging innovators developing complement-based therapies across a range of disease areas.

Attendees will gain actionable insights across the full complement drug development lifecycle, from target discovery through to clinical translation and commercialization.

By attending, you will be able to:

• Learn from 25+ expert speakers spanning biotech, pharma and academia
• Discover novel complement targets beyond C3 and C5
  Benchmark next-generation modalities including siRNA, gene therapy and biologics
• Explore biomarker and target engagement strategies to de-risk development
• Assess new opportunities across CNS, ocular, autoimmune, oncology and renal indications
• Gain practical insights into clinical development, indication prioritization and commercialization strategies
• Build relationships with industry leaders and potential collaborators

Whether you are advancing an early-stage asset or optimizing a clinical-stage program, the summit provides practical learnings that can directly support pipeline progression and strategic decision-making.

As complement therapeutics continue to evolve rapidly, there has never been a greater need for the community to come together to share scientific insights, discuss development challenges and identify new opportunities for collaboration.

While virtual meetings can provide updates, face-to-face discussions enable the informal conversations, strategic introductions and scientific debates that often lead to meaningful partnerships and breakthrough ideas. The complement field remains a highly specialized community where learning from peers, understanding competitor strategies and discussing emerging data directly with experts can provide a significant advantage.

That's why the 10th Complement-Based Drug Development Summit comes at a timely moment, and offers 7+ hours of dedicated networking, providing opportunities to engage with complement leaders from large pharma, emerging biotechs, academia and solution providers in a focused setting built specifically for the complement ecosystem.

As the industry's only dedicated forum uniting complement leaders, the meeting serves as a central hub for discussing the latest scientific advances, forging strategic partnerships and shaping the future direction of complement-based drug development.

Networking is one of the most valuable aspects of attending the 10th Complement-Based Drug Development Summit. Beyond the scientific content, attendees have the opportunity to connect directly with companies developing first- and best-in-class complement therapeutics, as well as the experts supporting their success.

By networking with peers and industry leaders, attendees can:

• Benchmark development approaches against other complement programs
• Learn how companies are overcoming scientific and clinical challenges
• Discover emerging technologies and platform innovations
• Identify potential research and development partners
• Build relationships with key opinion leaders and complement experts
• Create new opportunities for collaboration and business growth

With senior representation from organizations including Genentech, Regeneron, Apellis Pharmaceuticals, Visterra, InflaRx and Complement Therapeutics, attendees gain access to a highly engaged audience actively driving innovation across the complement landscape.